National Cancer Institute Sponsored Trials
In November 2011, Exelixis entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP). The CRADA reflects a commitment by NCI-CTEP to support the investigation of cabozantinib's potential in a wide variety of cancers, providing for the initiation of as many as 20 active clinical trials each year for a five-year period. As such, this agreement enables us to expand the cabozantinib development program by substantially increasing the number of indications and disease settings in which it is being investigated.
You can access a detailed list of cabozantinib clinical studies, including NCI-CTEP trials, at www.ClinicalTrials.gov. For further information regarding all clinical trials, please contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at email@example.com.